Share on StockTwits

Analysts at Stephens started coverage on shares of MedAssets (NASDAQ:MDAS) in a research report issued to clients and investors on Tuesday. The firm set an “equal weight” rating and a $20.00 price target on the stock. Stephens’ target price would suggest a potential downside of 14.89% from the company’s current price.

Several other analysts have also recently commented on the stock. Analysts at Raymond James reiterated an “outperform” rating on shares of MedAssets in a research note on Thursday, May 1st. They now have a $25.00 price target on the stock. Separately, analysts at Sterne Agee reiterated a “buy” rating on shares of MedAssets in a research note on Thursday, May 1st. They now have a $29.00 price target on the stock. Finally, analysts at JPMorgan Chase & Co. reiterated a “neutral” rating on shares of MedAssets in a research note on Thursday, May 1st. They now have a $22.00 price target on the stock. Ten analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $25.45.

Shares of MedAssets (NASDAQ:MDAS) opened at 23.50 on Tuesday. MedAssets has a one year low of $16.31 and a one year high of $26.58. The stock has a 50-day moving average of $23.53 and a 200-day moving average of $22.28. The company has a market cap of $1.433 billion and a P/E ratio of 52.57.

MedAssets (NASDAQ:MDAS) last announced its earnings results on Wednesday, April 30th. The company reported $0.32 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.33 by $0.01. On average, analysts predict that MedAssets will post $1.37 earnings per share for the current fiscal year.

MedAssets, Inc (NASDAQ:MDAS) provides technology-enabled products and services.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.